WEED Australia Ltd.’s corporate strategy is to become a leader in
cannabis and hemp research and development. To support this goal WEED Australia Ltd. has assembled a highly qualified team of wellrespected Ph.D.’s, scientists, researchers and business experts with the goal of establishing a domestic and export industry.

WEED, Inc. intends to enter into an exclusive license and assignment agreement with Yissum Research
Development Company of the Hebrew University of Jerusalem Ltd., Israel. The agreement is for five patents, technology and know-how relating to formulations for the administration and delivery of cannabinoid compounds. These patents were developed by Prof. Elka Touitou at the Hebrew University of Jerusalem. WEED Israel Cannabis Ltd. is currently obtaining licenses to grow, cultivate, process, extract, and manufacture cannabis derived products for the Israeli domestic and broader international markets.

Sangre BioSciences is currently in the process of conducting a
comprehensive Cannabis Genome Study to complete a global genomic classification of the cannabis plant genus. Sangre BioSciences is focused on a genomics-based cannabis breeding program that will produce new, genetically enhanced strains of cannabis that express the desired plant characteristics for strain specific and disease specific treatments and therapies for both humans and animals.

WEED Hong Kong Limited is a special purpose holding company for the development of the company’s patents, trademarks, copyrights and intellectual property for the company and brands of WEED Inc. on a global basis. Glenn E Martin, Director, President, CEO. Nicole Marie Breen, Director and company Treasurer. Ed Lehman, of Lehman, Le and Xu Corporate Services Limited, is appointed the corporate secretary. Registered office: Lehman, Lee and Xu. Suite 3313, Tower One, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong.

The Cannabis Institute of Australia, a wholly owned non-profit division of WEED Australia Ltd., was formed with the goal of creating a Scientific Advisory Council to establish national protocols and procedures backed by scientific research. With its network of PhD’s and doctors across Australia, The Cannabis Institute of Australia hopes to perfect strain specific, disease-specific treatments, therapies and products for both humans and animals with a special focus on the opioid crisis. Educating Australian MD’s & naturopathic doctors about the value of cannabinoid research, products and treatments is key to implementing national medical cannabis and treatment programs.

HEMP BioSciences of Arizona was established in 2021 by WEED, Inc. to research and study the hemp plant, both industrial and CBD strains, to create forward looking cultivation techniques and to find new methods of extracting cannabinoid compounds for use in
medical applications. HEMP BioSciences of Arizona will be the non-profit arm of WEED, Inc.’s American domestic operation with the goal of advancing the scientific mission of the company.